公开(公告)号：US20170129779A1

公开(公告)日：2017-05-11

申请号：US15409659

申请日：2017-01-19

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: C01B17/64 ,  A61K33/04 ,  A61K9/00

CPC classification number: C01B17/64 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06 ,  C01P2006/80 ,  Y10T436/23

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

公开(公告)号：US20130287676A1

公开(公告)日：2013-10-31

申请号：US13927241

申请日：2013-06-26

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: C01B17/64

CPC classification number: C01B17/64 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06 ,  C01P2006/80 ,  Y10T436/23

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Abstract translation: 本文提供药学上可接受的硫代硫酸钠及其药物组合物。 本文还提供了用于测定含硫代硫酸钠的样品中的总不可清除的有机碳的方法。 本文还提供了用于生产药学上可接受的硫代硫酸钠的方法。 本文还提供了包括施用药学上可接受的硫代硫酸钠的治疗方法。

公开(公告)号：US20210100833A1

公开(公告)日：2021-04-08

申请号：US17126329

申请日：2020-12-18

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Anthony James Lepine ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: A61K33/00 ,  C01B21/50 ,  A61P17/00 ,  A61P9/00 ,  A61P43/00 ,  A61P11/00 ,  A61K31/17 ,  A61K31/4418 ,  A61K31/4709 ,  A61K31/519 ,  A61K9/08 ,  A61K9/00

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

公开(公告)号：US20180256638A1

公开(公告)日：2018-09-13

申请号：US15973659

申请日：2018-05-08

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Anthony James Lepine ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: A61K33/00 ,  A61K31/4709 ,  A61K9/08 ,  A61K31/519 ,  A61K31/4418 ,  A61K31/17 ,  C01B21/50 ,  A61K9/00

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

公开(公告)号：US20220063999A1

公开(公告)日：2022-03-03

申请号：US17469006

申请日：2021-09-08

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: C01B17/64 ,  A61K33/14 ,  A61K33/22 ,  A61K33/04 ,  A61K31/404 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K45/06 ,  A61K33/00 ,  A61K9/00 ,  A61K31/4418 ,  A61K31/727

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

公开(公告)号：US20190100432A1

公开(公告)日：2019-04-04

申请号：US16208667

申请日：2018-12-04

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: C01B17/64 ,  A61K9/00 ,  A61K45/06 ,  A61K31/60 ,  A61K31/573 ,  A61K31/519 ,  A61K31/404 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K31/4418 ,  A61K31/727 ,  A61K33/00

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

公开(公告)号：US20150072025A1

公开(公告)日：2015-03-12

申请号：US14547255

申请日：2014-11-19

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Anthony James Lepine ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: A61K33/00 ,  A61K31/17 ,  A61K31/519 ,  A61K31/4418 ,  A61K31/4709

CPC classification number: A61K33/00 ,  A61K9/0019 ,  A61K9/08 ,  A61K31/17 ,  A61K31/4418 ,  A61K31/4709 ,  A61K31/519 ,  C01B21/50 ,  Y10T436/204998

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Abstract translation: 本文提供药学上可接受的亚硝酸钠及其药物组合物。 本文还提供了用于测定含亚硝酸钠的样品中的总非挥发性有机碳的方法。 本文还提供了用于生产药学上可接受的亚硝酸钠的方法。 本文还进一步提供了包括给药药学上可接受的亚硝酸钠的治疗方法。

公开(公告)号：US20140302179A1

公开(公告)日：2014-10-09

申请号：US14310133

申请日：2014-06-20

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: A61K33/04 ,  A61K33/00

CPC classification number: C01B17/64 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06 ,  C01P2006/80 ,  Y10T436/23

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

公开(公告)号：US20250042740A1

公开(公告)日：2025-02-06

申请号：US18805274

申请日：2024-08-14

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: C01B17/64 ,  A61K9/00 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

公开(公告)号：US20240101422A1

公开(公告)日：2024-03-28

申请号：US18225852

申请日：2023-07-25

Applicant: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals

Inventor： Craig Sherman ,  Catherine Marie Smith ,  Kevin Robert Wirtz ,  Erich Schulze

IPC: C01B17/64 ,  A61K9/00 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06

CPC classification number: C01B17/64 ,  A61K9/0014 ,  A61K9/0019 ,  A61K31/404 ,  A61K31/4418 ,  A61K31/519 ,  A61K31/573 ,  A61K31/60 ,  A61K31/727 ,  A61K33/00 ,  A61K33/04 ,  A61K33/14 ,  A61K33/22 ,  A61K45/06 ,  C01P2006/80 ,  Y10T436/23

Abstract: Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.